A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022
This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.
Received in the Senate.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Became Public Law No: 117-180.
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line